Daiichi Sankyo

1. Novel delivery platforms or organ (ex. CNS, lung, kidney, cancer, immune cells, heart, etc.) selective targeting ligands for antisense oligonucleotides, siRNA or mRNA

2. Novel nanoparticle-based DDS technology for CNS or cancer-targeting

1. Novel AAV capsid library platform/technology to isolate promising novel capsids in vivo
2. Novel technologies which can enhance gene expression or durability for in vivo gene therapy
3. Novel gene silencing/suppression technology/novel protein that show high suppression efficiency and can be delivered by viral vector

Novel technologies for adoptive T cell therapy

Novel research on glial cell function which can reveal relevance of the progression of neurodegenerative diseases. Ideas with high originality regarding neuroinflammation, cellular metabolism and senescence are of particular interest.

1. Unique antibodies or binders, applicable to mono- or multi-specific antibodies and/or cell therapy, against tumor-associated antigens, which include tumor, immune, and stromal cell targets
2. Pancreatic ducutal adenocarcinoma (PDAC) models which reflects human PDAC features, and better than known genetically engineered mouse models (GEMM) like KPC (KRAS, TP53)